BR112013008573A2 - citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer. - Google Patents

citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.

Info

Publication number
BR112013008573A2
BR112013008573A2 BR112013008573A BR112013008573A BR112013008573A2 BR 112013008573 A2 BR112013008573 A2 BR 112013008573A2 BR 112013008573 A BR112013008573 A BR 112013008573A BR 112013008573 A BR112013008573 A BR 112013008573A BR 112013008573 A2 BR112013008573 A2 BR 112013008573A2
Authority
BR
Brazil
Prior art keywords
glatiramer acetate
human subject
concentration
clinical response
indicators
Prior art date
Application number
BR112013008573A
Other languages
English (en)
Inventor
Jacqueline Y Smith
Lloyd H Kasper
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112013008573A2 publication Critical patent/BR112013008573A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

biomarcadores de citocinas como biomarcadores preditivos da resposta clínica para o acetato de glatirâmer. um método para tratamento de um sujeito humano que padece de esclerose múltipla ou de um único ataque clínico consistente com a esclerose múltipla, com uma composição farmacêutica compreendendo acetato de glatiramer, e um transportador farmaceuticamente aceitável, compreendendo as etapas de determinar se o sujeito humano é um acetato de glatiramer, avaliando uma resposta biomarcador selecionado a partir do grupo consistindo de il-17 de concentrado, a concentração de tnf-<244>, il-2 de concentração, a concentração, ou uma combinação destes, no sangue de sujeito humano e administrar a composição farmacêutica compreendendo acetato de glatiramer e um veículo farmaceuticamente veículo aceitável ao sujeito humano apenas se o sujeito humano é identificado como um acetato de glatiramer respondedor.
BR112013008573A 2010-10-11 2011-10-10 citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer. BR112013008573A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39196810P 2010-10-11 2010-10-11
PCT/US2011/055588 WO2012051106A1 (en) 2010-10-11 2011-10-10 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

Publications (1)

Publication Number Publication Date
BR112013008573A2 true BR112013008573A2 (pt) 2016-07-12

Family

ID=45938670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008573A BR112013008573A2 (pt) 2010-10-11 2011-10-10 citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.

Country Status (15)

Country Link
US (3) US8709433B2 (pt)
EP (1) EP2627669B1 (pt)
JP (2) JP2013541010A (pt)
KR (1) KR20140019296A (pt)
AU (1) AU2011313842B2 (pt)
BR (1) BR112013008573A2 (pt)
CA (1) CA2814500A1 (pt)
EA (1) EA025780B1 (pt)
ES (1) ES2602977T3 (pt)
IL (1) IL225118A (pt)
MX (1) MX347871B (pt)
NZ (2) NZ703122A (pt)
PL (1) PL2627669T3 (pt)
PT (1) PT2627669T (pt)
WO (1) WO2012051106A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
EP2765857A4 (en) 2011-10-10 2015-12-09 Teva Pharma SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CA2903805A1 (en) 2013-03-14 2014-10-02 Mylan Inc. Glatiramer acetate response biomarker mrna potency assay
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2928084A1 (en) 2013-10-24 2015-04-30 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US20160213633A1 (en) * 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ES2327301T3 (es) 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico.
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
DE60120648D1 (de) 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
WO2001093828A1 (en) 2000-06-05 2001-12-13 Teva Pharmaceuticals Industries, Ltd. The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093893A2 (en) 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
NZ533356A (en) 2001-12-06 2006-10-27 Yeda Res & Dev Vaccine and method for treatment of motor neurone diseases
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
ATE548045T1 (de) 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
WO2004064717A2 (en) 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2525771A1 (en) 2003-05-14 2004-12-02 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
CA2540701A1 (en) 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Proteins expressed in nk cells
CA2541445A1 (en) 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US20090048181A1 (en) * 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
KR101317131B1 (ko) 2004-09-09 2013-10-10 테바 파마슈티컬 인더스트리즈 리미티드 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
HUE028833T2 (en) 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
JP5297653B2 (ja) 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
CN101111252A (zh) 2005-02-02 2008-01-23 泰华制药工业有限公司 一种通过氢解反应生产多肽混合物的方法
ES2420404T3 (es) 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
US20070059798A1 (en) 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
WO2007041245A2 (en) * 2005-09-29 2007-04-12 Biogen Idec Ma Inc. Biomarkers for multiple sclerosis and methods of use thereof
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
EP2046817B1 (en) 2006-07-05 2009-12-16 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
EP2171044A1 (en) * 2007-06-25 2010-04-07 Vertex Pharmceuticals Incorporated Th-17 cells
CN101877963A (zh) 2007-11-28 2010-11-03 泰华制药工业有限公司 延缓临床确诊的多发性硬化症发作的方法
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
WO2010033951A2 (en) * 2008-09-19 2010-03-25 University Of Utah Research Foundation Methods for identification and prediction of multiple sclerosis disease and therapy response
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
PT2275086E (pt) 2009-07-15 2012-05-18 Teva Pharma Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
EP2765857A4 (en) 2011-10-10 2015-12-09 Teva Pharma SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
US20150328277A1 (en) 2012-12-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Oral transmucosal delivery of glatiramer acetate
CA2895359A1 (en) 2012-12-21 2014-06-26 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate
KR20150111945A (ko) 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
US20140271630A1 (en) 2013-03-12 2014-09-18 Teva Pharmaceutical Industries, Ltd. Rituximab induction therapy followed by glatiramer acetate therapy
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Also Published As

Publication number Publication date
IL225118A (en) 2017-10-31
EP2627669B1 (en) 2016-08-17
EA025780B1 (ru) 2017-01-30
US9625473B2 (en) 2017-04-18
AU2011313842B2 (en) 2016-12-15
ES2602977T3 (es) 2017-02-23
PT2627669T (pt) 2016-11-24
MX347871B (es) 2017-05-16
AU2011313842A1 (en) 2013-05-30
EA201390543A1 (ru) 2013-09-30
US20120121619A1 (en) 2012-05-17
MX2013003929A (es) 2013-07-05
CA2814500A1 (en) 2012-04-19
NZ609938A (en) 2015-11-27
US8709433B2 (en) 2014-04-29
US20150241446A1 (en) 2015-08-27
WO2012051106A1 (en) 2012-04-19
NZ703122A (en) 2016-06-24
JP2013541010A (ja) 2013-11-07
JP2016188214A (ja) 2016-11-04
PL2627669T3 (pl) 2017-02-28
EP2627669A4 (en) 2014-04-09
US20140294899A1 (en) 2014-10-02
US9063153B2 (en) 2015-06-23
EP2627669A1 (en) 2013-08-21
KR20140019296A (ko) 2014-02-14

Similar Documents

Publication Publication Date Title
BR112013008573A2 (pt) citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
Ferrucci et al. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
BRPI0906858B8 (pt) métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer.
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
BR112012008665A2 (pt) tratamento de câncer
ECSP11011297A (es) Proteinas ligadoras il-17
MX366653B (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
WO2011015602A3 (en) Lung cancer biomarkers
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
BRPI0917612A2 (pt) &#39;&#39;sistema configurado para determinar uma elastância e uma resistência da respiração de um individuo e método de determinação de uma elastância e uma resistência da respiração de um individuo&#39;&#39;
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
WO2012075023A3 (en) Neoantibodies for diagnosing tissue injury
Chen et al. Dysregulation of striatal dopamine D2/D3 receptor-mediated by hypocretin induces depressive behaviors in rats
WO2011158016A3 (en) Assay
WO2014169011A3 (en) Methods for treating immune diseases
BR112014002347A2 (pt) método in vitro para detecção de predisposição ou de diagnóstico e/ou prognóstico de uma deposição anormal de proteínas da matriz extracelular (ecmp), método para seleção de um composto terapêutico para um paciente e método in vitro para determinar a probabilidade de um paciente afetado com uma infecção viral responder a um tratamento com um agente antiviral e/ou um interferon
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
WO2011073905A8 (en) Novel tumor markers
WO2013090965A3 (de) Zusammensetzung enthaltend antikörper gegen gluten und gerbstoffe
UA95956C2 (uk) Набір для визначення mage-а3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.